title: Increase of interleukin-18 serum levels after engraftment correlates with acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation.
abstract: OBJECTIVE
  Acute graft-versus-host disease (GvHD) is a constant and severe complication after allogeneic stem cell transplantation regularly involving skin, liver, gut, and lungs. The cytokine interleukin-18 (IL-18) has been shown to increase in patients who develop acute GvHD after bone marrow tranplantation (BMT).
  
  
  METHODS
  Here, we measured IL-18 serum levels after peripheral blood stem cell transplantation (PBSCT) at several characteristic time points in 24 patients (median age 46 years). Patients received a median of 7.3 x 10(6)/kg bodyweight CD34-positive blood stem cells from HLA-matched family donors (n = 5), matched unrelated donors (n = 18), and one mismatched unrelated donor. GvHD prophylaxis consisted of cyclosporin A alone or combined with methotrexate and/or mycophenolate mofetil.
  
  
  RESULTS
  In 14 patients we observed no GvHD or only GvHD grade I whereas ten patients developed GvHD grade II-IV post transplant. Low, intermediate, and high levels of serum IL-18 were found in patients after allogeneic PBSCT independently of GvHD after transplantation. In contrast to GvHD arising after BMT, there was no clear correlation between absolute IL-18 serum levels and GvHD grade after PBSCT. However, the individual time course of IL-18 serum level after engraftment correlates with acute GvHD after PBSCT. In detail, an increase of serum IL-18 of at least 1.6-fold after engraftment is associated with acute GvHD II or higher with a sensitivity of three out of four. Using the 1.6 "cut-off" for IL-18 increase after engraftment, a specificity of up to 100% can be achieved.
  
  
  CONCLUSIONS
  The time course of IL-18 serum levels might be used for GvHD prediction after PBSCT comparable to absolute serum levels after BMT.
authors.affiliation: Mildred Scheel Station für Knochenmarktransplantation, Department of Internal Medicine II, Friedrich Schiller University, Jena, Germany. sebastian.scholl@med.uni-jena.de
authors.forename: Sebastian
authors.initials: S
authors.lastname: Scholl
authors.forename: Herbert G
authors.initials: HG
authors.lastname: Sayer
authors.forename: Lars-Olof
authors.initials: LO
authors.lastname: Mügge
authors.forename: Christoph
authors.initials: C
authors.lastname: Kasper
authors.forename: Marko
authors.initials: M
authors.lastname: Pietraszczyk
authors.forename: Kay-Oliver
authors.initials: KO
authors.lastname: Kliche
authors.forename: Joachim H
authors.initials: JH
authors.lastname: Clement
authors.forename: Klaus
authors.initials: K
authors.lastname: Höffken
mesh_terms: D000328:Adult; D005260:Female; D006086:Graft vs Host Disease / Q000097:blood / Q000209:etiology*; D006801:Humans; D020382:Interleukin-18 / Q000097:blood*; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects*; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous
chemical_list: D020382:Interleukin-18